University Hospital, Brest
chu-brest.frTotal trials
595
Active
153
Phase 3
46
Total enrollment
249,065
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 30 of 30 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Low molecular weight heparin | — | — | — | — | — | 1 | |
| Blood sample | — | — | — | — | 3 | ||
| Saliva sample | — | — | — | — | 3 | ||
| Urine sample | — | — | — | — | 2 | ||
| Cannabis oil | — | — | — | — | — | 1 | |
| Propofol + analgesic drug | — | — | — | — | — | 1 | |
| Isoflurane + analgesic drug | — | — | — | — | — | 1 | |
| Apllication of cream | — | — | — | — | — | 1 | |
| ICG | — | — | — | — | — | 1 | |
| Botulinum toxin type A | — | — | — | — | — | 1 | |
| Capsaicin 8% patch | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| Pembrolizumab and Chemotherapy drugs | — | — | — | — | — | 1 | |
| Experimenta group (standard of care + Methoxyflurane). | — | — | — | — | — | 1 | |
| control group (standard of care + placebo). | — | — | — | — | — | 1 | |
| Baricitinib 4 MG Oral | — | — | — | — | — | 1 | |
| Baricitinib 2 MG Oral | — | — | — | — | — | 1 | |
| MEOPA | — | — | — | — | — | 1 | |
| Direct Oral Anticoagulants | — | — | — | — | — | 1 | |
| Low-dose aspirin | — | — | — | — | — | 1 | |
| Stood sample | — | — | — | — | — | 1 | |
| high flow oxygen therapy rate adjusted of lung volumes measured | — | — | — | — | — | 1 | |
| Naloxegol | — | — | — | — | — | 1 | |
| Stool sample | — | — | — | — | — | 1 | |
| Tissue sample | — | — | — | — | — | 1 | |
| Botulinum toxin | — | — | — | — | — | 1 | |
| biological sample | — | — | — | — | — | 1 | |
| Biologic sample | — | — | — | — | — | 1 | |
| matching genotype with phenotype | — | — | — | — | — | 1 | |
| Biological samples | — | — | — | — | — | 1 |
Next readouts
- 2025-08
- 2025-10-31
- 2025-12-22
- 2026-02-01
- 2026-03-15
- 2026-04-05
- 2026-06-22
- 2026-10
- 2026-11
- 2026-12-31
Top conditions
- Pulmonary Embolism13
- Venous Thromboembolism11
- Pruritus9
- Cystic Fibrosis9
- Chronic Obstructive Pulmonary Disease8
- Polymyalgia Rheumatica8
- COPD6
- Cerebral Palsy6
Frequently asked questions about University Hospital, Brest
- How many clinical trials does University Hospital, Brest have on ClinicalTrials.gov?
- University Hospital, Brest is listed as the lead sponsor on 595 clinical trials in ClinicalTrials.gov, 153 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Brest's trials are in Phase 3?
- 46 of University Hospital, Brest's trials are in Phase 3, spread across 30 active drug programs.
- What therapeutic areas does University Hospital, Brest focus on?
- University Hospital, Brest's most-studied conditions on ClinicalTrials.gov are Pulmonary Embolism, Venous Thromboembolism, Pruritus, Cystic Fibrosis, Chronic Obstructive Pulmonary Disease.
- When are University Hospital, Brest's next clinical trial readouts?
- University Hospital, Brest has 10 upcoming primary-completion readouts tracked here; the soonest is “Comparison of an Inhaled Sedation Strategy to an Intravenous Sedation Strategy in Intensive Care Unit Patients Treated With Invasive Mechanical Ventilation”, expected around 2025-08.